Correlation Between TPMT Polymorphisms and Azathioprine Toxicity in the Treatment of Inflammatory Bowel Disease: A Meta Analysis

董显文,郑青,沈骏,邱云,朱明明,徐锡涛,冉志华
DOI: https://doi.org/10.3969/j.issn.1008-7125.2010.07.004
2010-01-01
Abstract:Background: The efficacy of azathioprine (AZA) in the treatment of inflammatory bowel disease (IBD) is well established. However, severe side effects limit its use in some patients. The impact of thiopurine S-methyltrarlsferase (TPMT) polymorphisms on AZA toxicity has been evaluated in several studies but with varying outcomes. Aims: To systematically evaluate the correlation between TPMT polymorphisms and AZA-induced side effects in IBD patients. Methods: Eligible articles that compared TPMT polymorphisms between AZA-tolerant and-intolerant adult IBD patients were collected from electronic databases. The outcome measure examined was the OR for TPMT gene mutation rate between IBD patients with and without AZA-induced overall side effects, bone marrow toxicity, hepatotoxicity and pancreatitis. Sensitivity analysis was also performed. The publication bias was tested by funnel plot. Results: Eight studies including a total of 1322 participants met our inclusion criteria. The OR for TPMT gene mutation rate between IBD patients with and without AZA-induced overall side effects and bone marrow toxicity were 2.93 (95% CI: 1.68-5.09, P0.01) and 5.82 (95% CI: 2.93-11.55, P0.01), respectively. The OR for TPMT gene mutation rate between IBD patients with and without AZA-indueed hepatotoxicity and pancreatitis were 1.51 (95% CI: 0.54-4.19, P=0.43) and 1.02 (95% CI: 0.26-3.99, P=0.98), respectively. Conclusions: TPMT polymorphisms are associated with AZA-indueed overall side effects and bone marrow toxicity, but not with hepatotoxieity and pancreatitis.
What problem does this paper attempt to address?